三阴性乳腺癌新辅助化疗患者肠道微生物组组成特征。

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

机构信息

Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.

Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

出版信息

Oncologist. 2023 Sep 7;28(9):e703-e711. doi: 10.1093/oncolo/oyad060.

INTRODUCTION

Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a better event-free survival. The role of gut microbiome in early TNBC is underexplored.

METHODS

Microbiome was analyzed by 16SrRNA sequencing.

RESULTS

Twenty-five patients with TNBC treated with neoadjuvant anthracycline/taxane-based chemotherapy were included. Fifty-six percent achieved a pCR. Fecal samples were collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 samples (90.7%) were suitable for microbiome analysis. At t0, pCR group showed a significantly higher α-diversity as compared with no-pCR, (P = .049). The PERMANOVA test on β-diversity highlighted a significant difference in terms of BMI (P = 0.039). Among patients with available matched samples at t0 and t1, no significant variation in microbiome composition was reported over time.

CONCLUSIONS

Fecal microbiome analysis in early TNBC is feasible and deserves further investigation in order to unravel its complex correlation with immunity and cancer.

简介

接受新辅助化疗后达到病理完全缓解（pCR）的三阴性乳腺癌（TNBC）患者无事件生存更好。肠道微生物组在早期 TNBC 中的作用尚未得到充分探索。

方法

通过 16SrRNA 测序分析微生物组。

结果

共纳入 25 例接受新辅助蒽环类/紫杉类化疗的 TNBC 患者。56%的患者达到 pCR。在化疗前（t0）、化疗后 1 周（t1）和 8 周（t2）采集粪便样本。总体而言，68/75 份样本（90.7%）适合进行微生物组分析。在 t0 时，pCR 组的 α 多样性明显高于无 pCR 组（P=0.049）。基于 BMI 的 PERMANOVA 检验显示β-多样性存在显著差异（P=0.039）。在有 t0 和 t1 时匹配样本的患者中，未报告微生物组组成随时间的显著变化。